Advertisement
Julie Zhang
Reporter, Business
Julie Zhang joined SCMP in 2025 as a business reporter. She was formerly with China Daily Hong Kong Edition for over five years, covering corporate earnings, IPOs, financial regulations, ESG, cryptocurrency and property markets. Her reporting garnered multiple Hong Kong News Awards and Hang Seng University's Business Journalism Award.
Julie Zhang joined SCMP in 2025 as a business reporter. She was formerly with China Daily Hong Kong Edition for over five years, covering corporate earnings, IPOs, financial regulations, ESG, cryptocurrency and property markets. Her reporting garnered multiple Hong Kong News Awards and Hang Seng University's Business Journalism Award.
Areas of Expertise:
Corporate finance, IPOSLanguages Spoken:
Cantonese, English, Mandarin
Hong Kong Monetary Authority widens scope of yuan finance to solidify status as ‘offshore laboratory’ for currency amid de-dollarisiation trend.
The city plans to process its first gold settlement on Tuesday, according to those familiar with the matter.
Global pharmaceutical firms are tapping into Chinese artificial intelligence assets before patents expire on blockbuster drugs, advancing AI-driven biotech.
Beijing’s anti-tax evasion campaign could expand, raising concerns that corporate earnings, cash flows and investor sentiment may be at risk.
Advertisement
The trend reflects a ‘growing relevance’ of Asian markets, while US investors pull back on gold holdings due to higher rates, inflation.
Royalty financing offers new cash source as global investors pursue Chinese drug breakthroughs despite US pressure, Royalty Pharma says.
With Chinese technology giants fuelling an ‘A-to-H’ listing boom, Hong Kong appears to be on the rise as their ‘fundraising venue of choice’.
Likang Life Sciences says it has developed a personalised vaccine using advanced tech to identify tumour-specific mutations.
Calls grow to further expand Hong Kong’s connect scheme with mainland China markets amid drive for deeper capital flows.
Average daily southbound turnover soared 84 per cent year on year to HK$124.1 billion, equal to 24 per cent of city’s total market turnover.
The move comes after European Central Bank chief urged global leaders to discuss undervaluation of the Chinese currency.
Goldman Sachs says pharmaceutical, biotech sectors could see strongest tailwinds, while car industry, tech hardware makers may struggle.
Cancer treatments remain the top research focus as Beijing’s drive to make biotech a strategic industry draws attention in Washington.
China’s biotech boom continues to attract Western drug makers even as Washington expands investment and technology controls.
Chinese brands, including BYD, Jaecoo and Wuling Motors, captured 17.6 per cent of Indonesia’s car market in the first quarter of 2026.
Chinese carmakers unveiled 14 smart vehicles in Hong Kong as they use the city to gauge overseas demand and refine global expansion plans.
AI server backlogs and supply chain strains push Kingboard to tap markets and expand circuit board output.
World Gold Council states about nine in 10 central banks will increase holdings as de-dollarisation trend continues amid global instability.
Chinese drug makers are increasingly relying on overseas licensing deals to reach global markets amid growing geopolitical tensions.
Exchange will review listing rules introduced since 2018 to consolidate its competitiveness in the global fundraising market.
Growing collaboration between multinational drug makers and Chinese companies not expected to slow after US move.
General Mills and Mölnlycke follow Starbucks, Burger King in forging partnerships to better tap local market insights.
A boom in outlicensing agreements leads to a debate over which Chinese firms may be first to break into overseas markets with own brands.
AI is transforming longevity as companies like METiS TechBio and Human Longevity use algorithms to combat ageing and predict health risks.
Shanghai-based pet food maker Fubei has filed an application for an initial public offering in Hong Kong.
The share-price surge came as promising cancer trial data overshadowed continuing scrutiny of China’s biotechnology sector by US lawmakers.
Hong Kong trading soars 536 per cent, firm says, while making no mention of US$61 million fine from China’s market watchdog.
Ivonescimab phase three trials reduce death risk by 34 per cent, as analysts predict it could transform non-small cell lung cancer therapy.
China’s gold reserves have grown for 18 straight months, country’s central bank says.
